These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Pharmacogenomics: an assessment of market conditions and competition. Grimaldi BA Find Brief; 2007 Mar; 10(3):1-4. PubMed ID: 17354334 [No Abstract] [Full Text] [Related]
23. There's still gold in them thar pills. O'Reilly B Fortune; 2001 Jul; 144(2):58-62, 66-8, 70. PubMed ID: 11471355 [No Abstract] [Full Text] [Related]
24. Evolution of pharmacogenomics. Somogy A Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663 [TBL] [Abstract][Full Text] [Related]
25. The biotech drug market. Lawrence S Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645 [No Abstract] [Full Text] [Related]
26. The impact of market volatility on the cell therapy industry. Brindley DA; Reeve BC; Sahlman WA; Bonfiglio GA; Davie NL; Culme-Seymour EJ; Mason C Cell Stem Cell; 2011 Nov; 9(5):397-401. PubMed ID: 22056137 [TBL] [Abstract][Full Text] [Related]
27. Biotech drug market steadily expands. Lawrence S Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279 [No Abstract] [Full Text] [Related]
29. [Commercial effectiveness of the pharmaceutical industry. Industry cost-effectiveness and customers value]. Mur Martà J; Vilardell Molas M Med Clin (Barc); 2004 May; 122(19):753-7. PubMed ID: 15171911 [No Abstract] [Full Text] [Related]
30. Drug companies accused of stalling tailored therapies. Sinha G Nat Med; 2006 Sep; 12(9):983. PubMed ID: 16960561 [No Abstract] [Full Text] [Related]
31. Creating incentives for genomic research to improve targeting of therapies. Evans BJ; Flockhart DA; Meslin EM Nat Med; 2004 Dec; 10(12):1289-91. PubMed ID: 15580246 [No Abstract] [Full Text] [Related]
32. Price check! An analysis of direct-to-consumer pharmaceutical marketing. Wakeam E Acad Med; 2009 Feb; 84(2):234-5. PubMed ID: 19174677 [No Abstract] [Full Text] [Related]
33. Tysabri back on market. Sheridan C Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111 [No Abstract] [Full Text] [Related]
34. MMA supports Gov. Pawlenty's call for study of drug-marketing costs. Minn Med; 2006 Aug; 89(8):23. PubMed ID: 16967878 [No Abstract] [Full Text] [Related]
35. Implications of pharmacogenomics for drug development. Kirk RJ; Hung JL; Horner SR; Perez JT Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536 [TBL] [Abstract][Full Text] [Related]
36. SNP market view: opportunities, technologies, and products. Wypgant M Biotechniques; 2002 Jun; Suppl():78-80, 82, 84 passim. PubMed ID: 12083402 [No Abstract] [Full Text] [Related]
37. Probiotics: from bench to market. Klein M; Sanders ME; Duong T; Young HA Ann N Y Acad Sci; 2010 Nov; 1212 Suppl 1(Suppl 1):E1-14. PubMed ID: 21105878 [TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomics: questions and concerns. Mahlknecht U; Voelter-Mahlknecht S Curr Med Res Opin; 2005 Jul; 21(7):1041-7. PubMed ID: 16004671 [TBL] [Abstract][Full Text] [Related]
39. Allergic rhinitis: market evolution. Clark MJ; Million RP Nat Rev Drug Discov; 2009 Apr; 8(4):271-2. PubMed ID: 19337269 [No Abstract] [Full Text] [Related]
40. Lifecycle management for recombinant protein production using mammalian cell culture technology. Moran E; Gammell P Adv Biochem Eng Biotechnol; 2014; 139():245-56. PubMed ID: 24196316 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]